Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker LKFT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Eli Samaha | 3.61M | 5.5% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Caraway Jackson Investments LLC | 3.61M | 5.5% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Madison Avenue GP, LLC | 3.61M | 5.5% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | EMAI Management, LLC | 3.61M | 5.5% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Madison Avenue Partners, LP | 3.61M | 5.5% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Madison Avenue International LP | 3.61M | 5.5% | SCHEDULE 13G ↗ |
| Oct 29, 2025 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 29, 2025 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 29, 2025 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Tang Capital Partners International, LP | 2.25M | 3.4% | SCHEDULE 13G ↗ |
| Oct 29, 2025 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Tang Capital Partners, LP | 3.31M | 5.0% | SCHEDULE 13G ↗ |
| Oct 29, 2025 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Kevin Tang | 5.56M | 8.4% | SCHEDULE 13G ↗ |
| Oct 29, 2025 | SCHEDULE 13G | LKFT Lakefront Biotherapeutics | Tang Capital Management, LLC | 5.56M | 8.4% | SCHEDULE 13G ↗ |
| Jul 28, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | EcoR1 Capital Fund, L.P. | 522,445 | 0.8% | SCHEDULE 13D/A ↗ |
| Jul 28, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | EcoR1 Capital Fund Qualified, L.P. | 8.19M | 12.4% | SCHEDULE 13D/A ↗ |
| Jul 28, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | Oleg Nodelman | 8.71M | 13.2% | SCHEDULE 13D/A ↗ |
| Jul 28, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | EcoR1 Capital, LLC | 8.71M | 13.2% | SCHEDULE 13D/A ↗ |
| May 19, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | EcoR1 Capital Fund, L.P. | 463,704 | 0.7% | SCHEDULE 13D/A ↗ |
| May 19, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | EcoR1 Capital Fund Qualified, L.P. | 7.34M | 11.1% | SCHEDULE 13D/A ↗ |
| May 19, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | Oleg Nodelman | 7.80M | 11.8% | SCHEDULE 13D/A ↗ |
| May 19, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | EcoR1 Capital, LLC | 7.80M | 11.8% | SCHEDULE 13D/A ↗ |
| Feb 14, 2025 | SCHEDULE 13D | LKFT Lakefront Biotherapeutics | Concentra Biosciences, LLC | 0 | 0.0% | SCHEDULE 13D ↗ |
| Feb 14, 2025 | SCHEDULE 13D | LKFT Lakefront Biotherapeutics | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13D ↗ |
| Feb 14, 2025 | SCHEDULE 13D | LKFT Lakefront Biotherapeutics | Tang Capital Partners III, Inc | 224,960 | 0.3% | SCHEDULE 13D ↗ |
| Feb 14, 2025 | SCHEDULE 13D | LKFT Lakefront Biotherapeutics | Tang Capital Partners International, LP | 1.96M | 3.0% | SCHEDULE 13D ↗ |
| Feb 14, 2025 | SCHEDULE 13D | LKFT Lakefront Biotherapeutics | Tang Capital Partners, LP | 2.72M | 4.2% | SCHEDULE 13D ↗ |
| Feb 14, 2025 | SCHEDULE 13D | LKFT Lakefront Biotherapeutics | Kevin Tang | 4.91M | 7.5% | SCHEDULE 13D ↗ |
| Feb 14, 2025 | SCHEDULE 13D | LKFT Lakefront Biotherapeutics | Tang Capital Management, LLC | 4.91M | 7.5% | SCHEDULE 13D ↗ |
| Jan 10, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | Gilead Therapeutics A1 Unlimited Company | 20.98M | 29.9% | SCHEDULE 13D/A ↗ |
| Jan 10, 2025 | SCHEDULE 13D/A (amended) | LKFT Lakefront Biotherapeutics | Gilead Sciences, Inc. | 20.98M | 29.9% | SCHEDULE 13D/A ↗ |
29 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 7:30 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances